Current and Previous Roles of Glen Clack

Translational and early clinical development of anti-cancer agents, from lead optimisation to clinical proof of concept in solid and haematological malignancies; both as monotherapy and combination with other anti-cancer treatments including small molecules, chemotherapy, radiotherapy and immune oncology agents.

The relevant biological effect areas of these compounds have included hormone manipulation, invasion, DNA damage repair, immune modulation, angiogenesis, MTOR/PI3K/AKT and MET pathways, anti-sense oligonucleotide, and tumour genetic drivers.

This includes the overall clinical, scientific & value content, risk benefit assessment and delivery of the medical science components to the projects to time & quality, the translational and clinical strategy, ethical and scientific integrity of the plans, studies and the product, and the risk management plan.


  • Provision of strategic advice in early phase clinical development
  • Global drug development experience through all phases of drug development
  • Development of small and large molecule anti-cancer compounds; as monotherapy and in combination with other anti-cancer treatments, including radiotherapy, in both solid and haematological malignancies
  • Experience of compounds in the following biological effect areas:
    • Endocrine manipulation
    • Tumour invasion
    • DNA damage repair
    • Immune modulation
    • Angiogenesis
    • MTOR/PI3K/AKT pathway
    • Anti-sense oligonucleotide
    • Cancer vaccines
    • Tumour genetic drivers
    • Thymidylate synthase inhibitors
  • Collaboration with regulatory authorities and academics to produce highly flexible and adaptive early phase clinical trial designs, that allow clinical studies to evolve in line with emerging data. These designs have been shown to be both faster in delivering proof of concept and more efficient
  • Delivery of US, European and Japanese regulatory submissions
  • Orphan status and accelerated approval opportunities
  • Active liaison with regulatory authorities, research groups and key opinion leaders


Chief Medical Officer

Modulus Oncology Ltd.


Oncology Drug Development Advisor

Cumulus Oncology Ltd.


Managing Director

Ailse Oncology Ltd., Lyme Green, Cheshire


Honorary Professor of Translational Medicine

Department of Oncology and Metabolism, Faculty of Medicine, University of Sheffield


MSc Module Tutor

'Introduction to Clinical Trials' modules of the Pharmaceutical Industry Advanced Training (PIAT) MSc and Model Based Drug Development MSc.

The School of Pharmacy and Pharmaceutical Sciences, Manchester University


Honorary Lecturer, Translational Science

The School of Medicine and School of Pharmacy, Manchester University


Honorary Research Fellow

The Section of Human Metabolism, Division of Clinical Sciences (North), Faculty of Medicine, University of Sheffield


Senior Medical Director, Oncology Translational Medicine Unit

AstraZeneca, Alderley Park, Cheshire


Medical Science Director, Early Phase Oncology

AstraZeneca, Alderley Park, Cheshire


Clinical Director, Early Phase Oncology

AstraZeneca, Alderley Park, Cheshire


Associate Clinical Director, Discovery Medicine (Oncology and Infection)

AstraZeneca, Alderley Park, Cheshire


Medical Adviser, Clinical Science (Oncology)/Oncology Research Physician, Discovery Medicine (Oncology)

AstraZeneca, Alderley Park, Cheshire


Medical Adviser, Experimental Medicine (Oncology)

AstraZeneca, Alderley Park, Cheshire


Medical Adviser, Clinical Science (Oncology)

Zeneca, then AstraZeneca


Surgical Trainee

In the National Health Service

Contact Us

Please fill in the contact form and we will get back to you as soon as possible.

Ailse Oncology Ltd
First Floor, Merchant Exchange
Waters Green
Cheshire SK11 6JX
United Kingdom

+44 7765 898619

IPSE member

We use cookies to personalise and enhance your experience on our site and improve the delivery of ads to you. Visit our Cookie Policy to learn more. By clicking 'accept', you agree to our use of cookies.